Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. (SLDB) is a biotechnology leader focused on developing gene therapies for rare neuromuscular and cardiac disorders, including Duchenne muscular dystrophy. This news hub provides investors and researchers with timely updates on the company's progress in advancing precision genetic medicines.
Access comprehensive coverage of SLDB's press releases, clinical trial milestones, financial disclosures, and strategic partnerships. Our curated news collection simplifies tracking critical developments in gene therapy innovation and regulatory advancements.
Key updates include announcements related to therapeutic pipelines, scientific collaborations, and market-moving events. Bookmark this page for streamlined access to verified information directly impacting SLDB's research trajectory and industry position.
Solid Biosciences (SLDB), focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences.
The company will present at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 2:15 pm ET, featuring President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks. A live webcast will be available on the company's website with a 90-day replay period.
Additionally, management will conduct one-on-one meetings at the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 17, 2025. Institutional investors can arrange meetings through their Needham or Piper Sandler representatives.
Solid Biosciences (NASDAQ: SLDB) has announced the granting of 43,374 restricted stock units (RSUs) to three newly hired employees. The RSUs are structured with a four-year vesting schedule, with 25% vesting annually on each grant date anniversary. The equity awards, issued under the Company's 2024 Inducement Stock Incentive Plan, are contingent upon continued employment through each vesting date. This compensation package was designed as an inducement for employment and complies with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (SLDB) has announced its upcoming presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, TX, scheduled for March 16-19, 2025. The presentation will focus on data from the Phase 1/2 INSPIRE DUCHENNE trial, which evaluates SGT-003, their next-generation gene therapy candidate for Duchenne muscular dystrophy.
The oral presentation titled 'Initial Experience from the INSPIRE DUCHENNE Phase I/II Study of SGT-003 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy' will be delivered by Dr. Kevin Flanigan from Nationwide Children's Hospital on March 19, 2025, at 1:45 PM CT in the Coronado ABCD location.
Solid Biosciences (NASDAQ: SLDB) reported its Q4 and full-year 2024 financial results, highlighting positive initial data from the INSPIRE DUCHENNE trial for SGT-003, their next-generation Duchenne gene therapy. The company ended 2024 with $148.9 million in cash and secured an additional $200 million through a February 2025 offering, extending runway into H1 2027.
Key developments include:
- FDA IND clearance for SGT-212 treating Friedreich's ataxia, with first participant dosing expected in H2 2025
- INSPIRE DUCHENNE trial showed promising results with mean microdystrophin expression of 110% and 78% dystrophin positive fibers
- Planned FDA meeting in mid-2025 to discuss accelerated approval pathways for SGT-003
Financial results show R&D expenses increased to $96.4 million for 2024 (vs $76.6M in 2023), while net loss widened to $124.7 million (vs $96.0M in 2023). The company maintains partnerships with 19 institutions for its AAV-SLB101 capsid technology.
Solid Biosciences (SLDB), a precision genetic medicines developer focused on neuromuscular and cardiac diseases, has announced its participation in three major investor conferences in Miami, FL during March 2025.
The company's leadership, including President and CEO Bo Cumbo and Chief Medical Officer Dr. Gabriel Brooks, will present at:
- Leerink Global Healthcare Conference - March 12, 2025, at 9:20 am ET
- Barclays 27th Annual Global Healthcare Conference - March 13, 2025, at 9:30 am ET
- Wedbush Securities' Cardiometabolic Conference - March 10, 2025
Live webcasts will be available on the company's website's Investors section, with replays archived for 30 days. Institutional investors can arrange meetings through Leerink or Barclays representatives.
Solid Biosciences (SLDB) has announced the granting of 11,950 restricted stock units (RSUs) to a newly hired employee. The RSUs are structured with a four-year vesting schedule, with 25% of the units vesting annually on each grant date anniversary. The equity award, issued under the Company's 2024 Inducement Stock Incentive Plan, serves as an employment inducement and complies with Nasdaq Listing Rule 5635(c)(4). The vesting is contingent upon the employee's continued service with the company through each vesting date.
Solid Biosciences (SLDB) has announced the pricing of an underwritten offering, consisting of 35,739,810 shares of common stock at $4.03 per share and pre-funded warrants to purchase 13,888,340 shares at $4.029 per warrant. The offering is expected to generate approximately $200.0 million in gross proceeds before deductions.
The pre-funded warrants will have an exercise price of $0.001 per share and will be immediately exercisable. The offering, expected to close around February 19, 2025, includes participation from notable investors such as Adage Capital Partners, Bain Capital Life Sciences, Invus, Perceptive Advisors, and RA Capital Management, among others.
Jefferies, Leerink Partners, and William Blair are serving as joint book-running managers, with H.C. Wainwright & Co. acting as lead manager for the offering.
Solid Biosciences (NASDAQ: SLDB) reported positive initial data from its Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy. The 90-day biopsy data from the first three participants showed an average microdystrophin expression of 110% and significant improvements in muscle health biomarkers.
The therapy has been well-tolerated in six participants dosed as of February 11, 2025, with no serious adverse events reported. Common adverse events included nausea, vomiting, fever, and transient declines in platelets. Early signals of potential cardiac benefits were observed.
The company continues enrollment, with the seventh participant dosed on February 17, 2025, and expects to dose approximately 20 total participants by Q4 2025. Solid Biosciences plans to request an FDA meeting in mid-2025 to discuss potential accelerated approval pathway for SGT-003.
Solid Biosciences (SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 31,101 restricted stock units (RSUs) to two new employees. The RSUs are structured to vest in four equal annual installments, with complete vesting occurring on the fourth anniversary of the grant date. The grants were issued under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.
Solid Biosciences (SLDB) has received Fast Track designation from the FDA for SGT-212, its dual-route gene therapy candidate for Friedreich's ataxia (FA). SGT-212 is designed to deliver the full-length frataxin gene through both intradentate nucleus and intravenous infusions to address neurologic, cardiac, and systemic manifestations of FA.
The Fast Track status, granted to products treating serious conditions with unmet medical needs, will facilitate more frequent FDA interactions and potential priority review eligibility. The company received FDA IND clearance on January 7th, 2025, and plans to initiate a Phase 1b trial in the second half of 2025. This first-in-human, open-label, multicenter study will evaluate safety and tolerability in both ambulatory and non-ambulatory FA patients, with a five-year follow-up period.
